Year: 2014
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: BACKGROUND: The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain when these agents are used with a protease inhibitor in second-line therapy for human immunodeficiency virus (HIV) infection in resource-limited settings. Removing the NRTIs or replacing them with raltegravir may provide a benefit. METHODS: In this open-label trial in sub-Saharan Africa, we randomly assigned 1277 adults and adolescents with HIV infection and first-line treatment failure to receive a ritonavir-boosted protease inhibitor (lopinavir-ritonavir) plus clinician-selected NRTIs (NRTI group, 426 patients), a protease inhibitor plus raltegravir in a superiority comparison (raltegravir group, 433 patients), or protease-inhibitor monotherapy after 12 weeks of induction therapy with raltegravir in a noninferiority comparison (monotherapy group, 418 patients). The primary composite end point, good HIV disease control, was defined as survival with no new World Health Organization stage 4 events, a CD4+ count of more than 250 cells per cubic millimeter, and a viral load of less than 10,000 copies per milliliter or 10,000 copies or more with no protease resistance mutations at week 96 and was analyzed with the use of imputation of data (≤4%). RESULTS: Good HIV disease control was achieved in 60% of the patients (mean, 255 patients) in the NRTI group, 64% of the patients (mean, 277) in the raltegravir group (P=0.21 for the comparison with the NRTI group; superiority of raltegravir not shown), and 55% of the patients (mean, 232) in the monotherapy group (noninferiority of monotherapy not shown, based on a 10-percentage-point margin). There was no significant difference in rates of grade 3 or 4 adverse events among the three groups (P=0.82). The viral load was less than 400 copies per milliliter in 86% of patients in the NRTI group, 86% in the raltegravir group (P=0.97), and 61% in the monotherapy group (P<0.001). CONCLUSIONS: When given with a protease inhibitor in second-line therapy, NRTIs retained substantial virologic activity without evidence of increased toxicity, and there was no advantage to replacing them with raltegravir. Virologic control was inferior with protease-inhibitor monotherapy. (Funded by European and Developing Countries Clinical Trials Partnership and others; EARNEST Current Controlled Trials number, ISRCTN37737787, and ClinicalTrials.gov number, NCT00988039.).
Source: New England Journal of Medicine
Authors: Nicholas I. Paton, Cissy Kityo, Anne Hoppe, Andrew Reid, Andrew Kambugu, Abbas Lugemwa, Joep J. van Oosterhout, Mary Kiconco, Abraham Siika, Raymond Mwebaze, Mary Abwola, George Abongomera, Aggrey Mweemba, Hillary Alima, Dickens Atwongyeire, Rose Nyirenda, Justine Boles, Jennifer Thompson, Dinah Tumukunde, Ennie Chidziva, Ivan Mambule, Jose R. Arribas, Philippa J. Easterbrook, James Hakim, A. Sarah Walker, Peter Mugyenyi
Institutions: University of Zimbabwe, National University of Singapore, MRC Clinical Trials Unit at UCL, University College London, Medical Research Council, Infectious Diseases Institute, Joint Clinical Research Centre, University of Malawi, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Dignitas International, Moi University, Nsambya Hospital, University Teaching Hospital, Hospital Universitario La Paz
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: HIV infection, second-line antiretroviral therapy, raltegravir, nucleoside reverse transcriptase inhibitors, protease inhibitors, lopinavir/ritonavir, protease inhibitor monotherapy, treatment failure, viral suppression, CD4 count, adverse events, resource-limited settings, sub-Saharan Africa, non-inferiority, integrase inhibitors
Open Access status: bronze
Funders: Abbott Laboratories, Pfizer, GlaxoSmithKline, World Health Organization, Gilead Sciences, Irish Aid, Wellcome Trust, ViiV Healthcare, National Institute for Health and Care Research, Medical Research Council, Instituto de Salud Carlos III, European and Developing Countries Clinical Trials Partnership
OpenAlex ID: W2125756020
